SEATTLE – Receptor Life Sciences (RLS) today announced the completion of a pre-investigational new drug (preIND) meeting with the U.S. Food and Drug Administration (FDA).
SEATTLE – Receptor Life Sciences announced today that the Company was granted a Schedule I research license from the United States Drug Enforcement Agency (DEA).